In our May issue of Pharmaceutical Executive FEATURES
Cover Story Pharm Exec’s Brand of the Year 2016 Casey McDonald
Pharm Exec’s 10th annual Brand of the Year is Bristol-Myers Squibb’s Opdivo, which has raced into the lead position in the treatment-shifting immuno-oncology space behind launches in three key cancers—melanoma, lung, and renal.
Interview Steering the Change: A Conversation with Jack Bailey, GSK’s US Pharmaceuticals Head William Looney
William Looney sits down with industry veteran Jack Bailey, who discusses his onboarding strategy as new president of GlaxoSmithKline’s US Pharmaceuticals business along with the progress of GSK’s novel—and often controversial—approaches to sales force compensation and transparency in information disclosure.
Value Pharma’s Big Push for Value Terry Hisey, Brett J. Davis To thrive in the “facts-beat-marketing-hype” future, companies must embrace a new operating model based on end-to-end (E2E) evidence management across the entire product life cycle.
ALSO IN THIS ISSUE Room with a View: Pharm Exec at the Vantage Point William Looney
The Boston biotech cluster proved an ideal setting for Pharm Exec's recent annual Editorial Advisory Board meeting, with the prevailing message that even the best environments for innovation require constant nurturing.
Pharm Exec’s Anti-Brand of the Year Casey McDonald
A look at this year’s 2016 Pharm Exec Brand of the Year and it would seem that the industry has much to be optimistic about. But a look at the winner and runner-up for our “Anti-Brand of the Year” award clarifies how many outside of the industry really see it.